MolDX: MammaPrint Billing and Coding Guidelines - R4

The MolDX: MammaPrint Billing and Coding guidelines coverage article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI) and 01312 (NV).

Summary of Changes:

  • Added verbiage: "MammaPrint™ is a qualitative in vitro diagnostic test service, performed in a single laboratory, using the gene expression profile of FFPE breast cancer tissue samples to assess a patients' risk for distant metastasis.

    MammaPrint was prospectively validated in the 6,693 patient MINDACT trial in early stage breast cancer, <5cm up to 3 positive lymph nodes and independent of receptor status."

Effective Date: January 1, 2018

View the locally hosted MolDX Medicare Coverage Article.

View a complete list of Noridian coverage articles.

  • Go to Noridian Medicare Coverage Articles webpage
  • Scroll to bottom of page
  • Select state/contract link of interest from applicable Active, Future, or Retired Articles column
  • Link will redirect you to CMS MCD
  • In CMS MCD, select corresponding article title to view a comprehensive revision history for this article

Last Updated Jun 11, 2019